|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1-4
|
|
pubmed:dateCreated |
2008-12-19
|
|
pubmed:abstractText |
SLOS is caused by a defect of cholesterol synthesis. HMG-CoA reductase inhibitors have been shown to improve biochemical parameters in this condition, but they have also been associated with CoQ10 deficiency in patients with hypercholesterolemia. The aim of this study was to analyse plasma and intracellular CoQ10 levels in SLOS patients and to determine the influence of HMG-CoA reductase inhibitors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0951-6433
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
32
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
191-7
|
|
pubmed:meshHeading |
pubmed-meshheading:19096116-Blood Platelets,
pubmed-meshheading:19096116-Child,
pubmed-meshheading:19096116-Child, Preschool,
pubmed-meshheading:19096116-Humans,
pubmed-meshheading:19096116-Hydroxymethylglutaryl-CoA Reductase Inhibitors,
pubmed-meshheading:19096116-Infant,
pubmed-meshheading:19096116-Simvastatin,
pubmed-meshheading:19096116-Smith-Lemli-Opitz Syndrome,
pubmed-meshheading:19096116-Ubiquinone,
pubmed-meshheading:19096116-Vitamin E
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Plasma and thrombocyte levels of coenzyme Q10 in children with Smith-Lemli-Opitz syndrome (SLOS) and the influence of HMG-CoA reductase inhibitors.
|
|
pubmed:affiliation |
Department of General Pediatrics, Division of Inborn Metabolic Diseases, University Hospital Heidelberg, Heidelberg, Germany. dorothea.haas@med.uni-heidelberg.de
|
|
pubmed:publicationType |
Journal Article
|
